IFW

TO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

HAM 2 TRADE

Paduation Act of 1005 no narrons are requir

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/618,444

Filing Date

July 11, 2003

First Named Inventor

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

314-300710US

Total Number of Pages in This Subr	nission Attorn	ey Docket Number	314-300710US				
ENCLOSURES (check all that apply)							
Fee Transmittal Form	Assignment Pap		After Allowance Communication to Group				
Fee Attached	Drawing(s)		Appeal Communication to Board of Appeals and Interferences				
Amendment / Response	Licensing-relate		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
After Final	Petition Routing and Accompany	Slip (PTO/SB/69) ing Petition	Proprietary Information				
Affidavits/declaration(s)	Petition to Converge Provisional Appl		Status Letter				
Extension of Time Request	Power of Attorne Change of Corre Address	ey, Revocation spondence	X Additional Enclosure(s) (please identify below):				
Express Abandonment Request	Terminal Disclaimer  Small Entity Statement		receipt acknowledgment postcard 4 References				
Information Disclosure Statemer	1 <b>L</b>		4 References				
Certified Copy of Priority Document(s)	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time						
Response to Missing Parts/ Incomplete Application	for consideration of the d		mon, including any extensions of time				
Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm or Individual name  Tom Hunter, F	eg. No. 38,498,	Quine Intellectua	al Property Law Group P.C.				
Signature Cm	Il.						
Date May 10, 2004							
CERTIFICATE OF MAILING							
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an							

Thereby certily that this correspondence is being facstrille transmitted to the OSPTO of deposited with the United States	
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date:	May 10, 2004

		•	
Typed or printed name	Chianti Appling )	4	
Signature	CADn	Date	5/10/04
	7 7 7		



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450, on May 10, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Chianti Apoling

Attorney Docket No. 314-300710US Client Ref. No. BI-335

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julie K. Andersen, et al.

Application No.: 10/618,444

Filed: July 11, 2003

For: IRON SEQUESTRATION OR

ELIMINATION TO REDUCE NEURODEGENERATION OR

PARKINSONS DISEASE

**PROGRESSION** 

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of International Search Report for corresponding International Application No. PCT/US03/22112. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Julie K. Andersen, et al. Application No.: 10/618,444

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter, J.D., Ph.D.

Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C. P.O. BOX 458 Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paper Reduction Act Substitute for form

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complete if Known 10/618,444 **Application Number** July 11, 2003 Filing Date First Named Inventor Julie K. Andersen Group Art Unit Unassigned **Examiner Name** Unassigned 314-300710US **Attorney Docket Number Date Submitted** May 10, 2004

(use as many sheets as necessary)

MAY 1 2 2004

			U.	S. PATENT DOCUMENTS		
Examiner Cite Initials No.		U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	Number	Kind Code (if known)	Cited Document MM-DD-YYYY			
	1	5,980,914		Gerolymatos	11/9/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Office	Foreign Patent Docume Number	ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
				, ,				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	2	BEN-SHACHAR ET AL. (1991) "The Iron Chelator Desferrioxamine (Desferal) Retards 6- Hydroxydopamine-Induced Degeneration of Nigrostriatal Dopamine Neurons" Journal of Neurochemistry, Vol. 56, No. 4, pp. 1441-1444	
	3	GALVANI ET AL. (1995) "Mitochondrial Toxicity of Iron and the Protective Role of Ferritin on Dopaminergic PC12 Cell Line" Toxic In Vitro Vol.9, No. 4, pp. 365-368	
	4	GASSEN ET AL. (1997) "The Potential Role in Iron Chelators in the Treatment of Parkinson's Disease and Related Neurological Disorders" Pharmacology & Toxicity Vol. 80, pp. 159-166	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.